Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Movement | Pneumococcal Vaccine Meets Late-Stage Clinical Trial Target, Vaxcyte (PCVX.US) Opens Over 50% Higher

US Stock Movement | Pneumococcal Vaccine Meets Late-Stage Clinical Trial Target, Vaxcyte (PCVX.US) Opens Over 50% Higher

智通财经智通财经2026/10/05 13:46
Show original

According to reports from Zhihu Finance APP, on Monday, Vaxcyte (PCVX.US) opened over 50% higher, with gains of around 53% at the time of publication, and a market capitalization of 12.8 billions USD. The surge comes after the company's pneumococcal vaccine met its late-stage clinical trial goals. According to company assessments, VAX-31—a 31-valent pneumococcal conjugate vaccine under investigation—achieved positive topline results in its pivotal Phase III OPUS-1 trial. The trial evaluated the candidate vaccine’s safety, tolerability, and immunogenicity in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 achieved all pre-specified co-primary immunogenicity endpoints in subjects aged 50 years and older. These trial results will serve as the foundation for the upcoming Biologics License Application to be submitted to the U.S. Food and Drug Administration.

According to Zhihui Finance APP, on Monday, Vaxcyte (PCVX.US) opened with a gap up of more than 50%. As of the time of writing, the stock had risen by approximately 53%, reaching a market capitalization of $12.8 billion. In terms of news, the company’s pneumococcal vaccine has achieved late-stage clinical trial goals. According to the company’s assessment, VAX-31—a 31-valent pneumococcal conjugate vaccine in the research stage—achieved positive topline results in its pivotal Phase III OPUS-1 trial. This trial evaluated the safety, tolerability, and immunogenicity of the candidate vaccine in adults for the prevention of invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 met all pre-specified co-primary immunogenicity endpoints in subjects aged 50 years and older. These trial results will lay the foundation for the upcoming Biologics License Application submission to the US Food and Drug Administration.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Moves | Major investment banks such as Morgan Stanley refute Toshiba expansion panic, Western Digital (WDC.US) and Seagate (STX.US) rebound sharply

According to Smart Finance APP, on Monday, Western Digital (WDC.US) surged over 7% at the opening, and Seagate Technology (STX.US) rose more than 5%. In the previous trading day, the news of Toshiba expanding its hard drive production led to a sector pullback, with both stocks dropping more than 10%. Subsequently, Morgan Stanley and Bernstein released research reports countering market panic, stating that the market had overreacted to the news of Toshiba's production expansion and that the actual impact on industry supply was limited. They noted that AI agency tasks and physical AI are driving additional storage demand, the supply-demand tension in the HDD sector will persist, and maintained their bullish ratings on Seagate and Western Digital. Among them, Morgan Stanley named Seagate as its top pick.

智通财经•2026/10/05 14:02
US Stock Moves | Major investment banks such as Morgan Stanley refute Toshiba expansion panic, Western Digital (WDC.US) and Seagate (STX.US) rebound sharply

Strategy (MSTR.US) reports Q3 digital asset floating profit of $21 billions, first return to profitability in four quarters

According to Jinse Finance, boosted by the late-summer cryptocurrency rally, the value of Strategy (MSTR.US)'s Bitcoin holdings increased, resulting in unrealized gains and marking its first profitable quarter in four quarters. The company, which is the world's largest publicly traded holder of Bitcoin, reported a $21 billion gain in its digital assets in the third quarter of 2026. Bitcoin rose 43% year-on-year in the third quarter.

智通财经•2026/10/05 13:57

TSMC rises over 1.6% to a record high, with a market value approaching 2.5 trillion USD.

TSMC opened higher and is now up over 1.6%, with its share price reaching a record high. The company’s total market capitalization is close to $2.5 trillion.

智通财经•2026/10/05 13:56